Rovadicitinib

Modify Date: 2025-09-17 21:27:24

Use of Rovadicitinib

Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC50 value <20 nM. Rovadicitinib also exhibits anti-inflammatory activity[1][2].

Name	Rovadicitinib

Description	Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC50 value <20 nM. Rovadicitinib also exhibits anti-inflammatory activity[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK
References	[1]. WHO Drug Informat ion - World Health Organization (WHO). [2]. Zhu Li, et al. Preparation of pyrrolopyrimidines as Janus kinase inhibitors: Preparation of pyrrolopyrimidines as Janus kinase inhibitors: World Intellectual Property Organization, WO2016095805. 2016-06-23. [3]. WHO Drug Information-World Health Organization (WHO).

Description

Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC50 value <20 nM. Rovadicitinib also exhibits anti-inflammatory activity[1][2].

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> JAK

Signaling Pathways >> Epigenetics >> JAK

Signaling Pathways >> Stem Cell/Wnt >> JAK

References

Molecular Formula	C₁₇H₁₉N₇
Molecular Weight	321.38
InChIKey	ZGENDZDSLYKCSI-CQSZACIVSA-N
SMILES	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)c(N)n1